New hypothesis for amyloid ??-protein in Alzheimer's disease

1992 ◽  
Vol &NA; (853) ◽  
pp. 2
Author(s):  
&NA;
2010 ◽  
Vol 999 (999) ◽  
pp. 1-16 ◽  
Author(s):  
L.F. Agnati ◽  
D. Guidolin ◽  
F. Baluska ◽  
G. Leo ◽  
P.W. Barlow ◽  
...  

2021 ◽  
Author(s):  
Paul C R Hopkins ◽  
Claire Troakes ◽  
Guy Tear

We previously identified Transmembrane and Coiled-Coil 2 (TMCC2) as a protein that forms complexes with both apolipoprotein E (apoE) and the amyloid protein precursor (APP) and which displayed differential affinity for apoE isoforms apoE3 and apoE4. Here we have for the first time examined TMCC2 in the human brain and found that it is affected by APOE genotype and brain region. We further observed that TMCC2 associates with the pathology of Alzheimer's disease in dense core and neuritic plaques. TMCC2 is therefore positioned to mediate impacts of apoE4 on Alzheimer's disease pathology.


2000 ◽  
Vol 2 (2) ◽  
pp. 101-110 ◽  

Alzheimer's disease (AD) is a disorder of two pathologies- plaques and tangles. The former have as a key constituent amyloid protein and the latter the microtubule-associaied protein tau. Genetics has demonstrated that changes in either protein are sufficient to cause dementia. The amyloid cascade hypothesis proposes that plaque-related changes precede tangle-related changes and positions amyloid as central to the degeneration of AD. All the evidence suggests this is correct, including evidence that presenil ins alter the processing of the amyloid precursor protein and evidence that disrupting the normal properties of tau underlies the related froniotemporal dementias. The amyloid cascade hypothesis has provided the basis for nearly a decade of intensive basic science - the skeleton of that hypothesis can now be fleshed out, and confidence is growing that this will result in useful disease-modifying therapies in the future.


Sign in / Sign up

Export Citation Format

Share Document